SG Americas Securities LLC Acquires New Stake in OptimizeRx Co. (NASDAQ:OPRX)

SG Americas Securities LLC acquired a new stake in shares of OptimizeRx Co. (NASDAQ:OPRX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 10,555 shares of the company’s stock, valued at approximately $51,000. SG Americas Securities LLC owned 0.06% of OptimizeRx at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in OPRX. Rice Hall James & Associates LLC increased its stake in shares of OptimizeRx by 24.0% during the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after acquiring an additional 119,306 shares during the period. Janney Montgomery Scott LLC bought a new stake in OptimizeRx during the third quarter worth approximately $810,000. Greenwood Capital Associates LLC boosted its holdings in OptimizeRx by 8.0% during the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock worth $520,000 after buying an additional 4,999 shares in the last quarter. Quest Partners LLC boosted its holdings in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after buying an additional 2,414 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

Insider Buying and Selling

In other news, CEO William J. Febbo bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the acquisition, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at $3,012,277.53. The trade was a 3.44 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 6.10% of the company’s stock.

OptimizeRx Trading Up 12.5 %

Shares of NASDAQ:OPRX opened at $6.29 on Friday. The firm has a fifty day moving average of $5.28 and a two-hundred day moving average of $6.42. The firm has a market capitalization of $115.86 million, a P/E ratio of -4.73 and a beta of 1.38. OptimizeRx Co. has a 12-month low of $3.78 and a 12-month high of $16.65. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. JMP Securities restated a “market outperform” rating and set a $8.00 target price on shares of OptimizeRx in a report on Thursday, February 6th. Lake Street Capital restated a “buy” rating and set a $11.00 target price on shares of OptimizeRx in a report on Tuesday, December 24th. Roth Mkm restated a “buy” rating and set a $16.00 target price (down from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Royal Bank of Canada restated a “sector perform” rating and set a $6.00 target price (down from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.06.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.